The Influence of geometrical and operational parameters on internal flow characteristics of Internally Mixing Twin-Fluid Y-Jet Atomizers

Internally mixing twin-fluid Y-jet atomizers are widely used in coal fired thermal power plants for start-up, oil-fired thermal power plants and industrial boilers. The flow through internally mixing Y-jet atomizers is numerically modeled using the compressible Navier-Stokes equations; Wall Modeled Large Eddy Simulations (WMLES) is used to resolve the turbulence with Large Eddy Simulations whereas the Prandtl Mixing Length Model is used for modeling the subgrid scale structures, which are affected by geometric and operational parameters. Moreover, the Volume-of-Fluid (VOF) method is used to capture the development and fragmentation of the liquid-gas interface within the Y-jet atomizer. The numerical results are compared with correlations available in open literature for the pressure drop; further results are presented for the multiphase flow regime maps available for vertical pipes. The results show that the mixing point pressure is strongly dependent on the mixing port diameter to airport diameter ratio, specifically for gas to liquid mass flowrate ratio (GLR) in the range 0.1 < GLR < 0.4; the mixing port length moderately affects the mixing point pressure while the angle between mixing and liquid ports is found not to have an appreciable effect. Moreover, it is found that the vertical pipe multiphase flow regime maps in the literature could be applied to the flow through the mixing port of the twin-fluid Y-jet atomizer. The main flow regimes found under the studied operational conditions are annular and wispy annular flow

Numerical modelling of in-nozzle flow transient effects and fuel atomization characteristics of an industrial atomizer

Internally mixing twin-fluid Y-jet atomizers are widely used in coal fired thermal power plants for start-up, oil-fired thermal power plants and industrial boilers. The present work is the first to numerically model the multiphase flow through twin fluid Y-jet atomizer as function of the various operating conditions affecting it. Two different detailed studies have been carried out. In the first study, the flow through internally mixing Y-jet atomizers is numerically modeled using the compressible Navier-Stokes equations; Wall Modeled Large Eddy Simulations (WMLES) is used to resolve the turbulence with Large Eddy Simulations whereas the Prandtl Mixing Length Model is used for modeling the subgrid scale structures, which are affected by geometric and operational parameters. Moreover, the Volume-of-Fluid (VOF) method is used to capture the development and fragmentation of the liquid-gas interface within the Y-jet atomizer. The numerical results are compared with correlations available in open literature for the pressure drop; further results are presented for the multiphase flow regime maps available for vertical pipes. The results show that the mixing point pressure is strongly dependent on the mixing port diameter to airport diameter ratio; the mixing port length moderately affects the mixing point pressure while the angle between mixing and liquid ports is found not to have an appreciable effect. Moreover, it is found that the vertical pipe multiphase flow regime maps in the literature could be applied to the flow through the mixing port of the twin-fluid Y-jet atomizer. The main flow regimes found under the studied operational conditions are annular and wispy annular flow. In the second study, the atomization mechanism of the gas-liquid multiphase flow through internally mixing twin-fluid Y-jet atomizer has been studied by examining both the internal and external flow patterns. Super-heated steam and Light Fuel Oil (LFO) are used as working fluids. VOF-to-DPM transition mechanism is utilized along with dynamic solution adaptive mesh refinement to predict the initial development and fragmentation of the gas-liquid interface through Volume-of-Fluid (VOF) formulations on a sufficiently fine mesh, while Discrete Phase Model (DPM) is used to predict the dispersed part of the spray on the coarser grid. Two operational parameters, namely gas-to-liquid mass flow rate ratio (GLR) and gas-to-liquid momentum ratio are compared; the latter is found to be an appropriate operational parameter to describe both the internal flow and atomization characteristics. It is confirmed that the variation in the flow patterns within the mixing-port of the atomizer coincides with the variation of the spatial distribution of the spray drops

Atomization Mechanism of Internally Mixing Twin-Fluid Y-Jet Atomizer

The atomization mechanism of the gas-liquid multiphase flow through an internally mixing twin-fluid Y-jet atomizer has been studied by examining both the internal and external flow patterns. Superheated steam and light fuel oil (LFO) are used as working fluids. The flow is numerically modeled using the compressible Navier-Stokes equations; the hybrid large eddy simulation approach through wall-modeled large eddy simulations (WMLES) is used to resolve the turbulence with the large eddy simulations, whereas the Prandtl mixing length model is used for modeling the subgrid-scale structures, which are affected by operational parameters. A volume-of-fluid to discrete phase model (VOF-to-DPM) transition mechanism is utilized along with dynamic solution-adaptive mesh refinement to predict the initial development and fragmentation of the gas-liquid interface through VOF formulations on a sufficiently fine mesh, while DPM is used to predict the dispersed part of the spray on the coarser grid. Two operational parameters, namely, gas-to-liquid mass flow rate ratio (GLR) and liquid-to-gas momentum ratio, are compared; the latter is found to be an appropriate operational parameter to describe both the internal flow and atomization characteristics. It is confirmed that the variation in the flow patterns within the mixing port of the atomizer coincides with the variation of the spatial distribution of the spray drops

Timing detectors with SiPM read-out for the MUSE experiment at PSI

The Muon Scattering Experiment at the Paul Scherrer Institute uses a mixed beam of electrons, muons, and pions, necessitating precise timing to identify the beam particles and reactions they cause. We describe the design and performance of three timing detectors using plastic scintillator read out with silicon photomultipliers that have been built for the experiment. The Beam Hodoscope, upstream of the scattering target, counts the beam flux and precisely times beam particles both to identify species and provide a starting time for time-of-flight measurements. The Beam Monitor, downstream of the scattering target, counts the unscattered beam flux, helps identify background in scattering events, and precisely times beam particles for time-of-flight measurements. The Beam Focus Monitor, mounted on the target ladder under the liquid hydrogen target inside the target vacuum chamber, is used in dedicated runs to sample the beam spot at three points near the target center, where the beam should be focused

Phytoremediation of heavy metal-contaminated sites: Eco-environmental concerns, field studies, sustainability issues and future prospects

Environmental contamination due to heavy metals (HMs) is of serious ecotoxicological concern worldwide because of their increasing use at industries. Due to non-biodegradable and persistent nature, HMs cause serious soil/water pollution and severe health hazards in living beings upon exposure. HMs can be genotoxic, carcinogenic, mutagenic, and teratogenic in nature even at low concentration. They may also act as endocrine disruptors and induce developmental as well as neurological disorders and thus, their removal from our natural environment is crucial for the rehabilitation of contaminated sites. To cope with HM pollution, phytoremediation has emerged as a low-cost and eco-sustainable solution to conventional physico-chemical cleanup methods that require high capital investment and labor alter soil properties and disturb soil microflora. Phytoremediation is a green technology wherein plants and associated microbes are used to remediate HM-contaminated sites to safeguard the environment and protect public health. Hence, in view of the above, the present paper aims to examine the feasibility of phytoremediation as a sustainable remediation technology for the management of metals-contaminated sites. Therefore, this paper provides an in-depth review on both the conventional and novel phytoremediation approaches, evaluate their efficacy to remove toxic metals from our natural environment, explore current scientific progresses, field experiences and sustainability issues and revise world over trends in phytoremediation research for its wider recognition and public acceptance as a sustainable remediation technology for the management of contaminated sites in 21st century

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Background: Casirivimab and imdevimab are non-competing monoclonal antibodies that bind to two different sites on the receptor binding domain of the SARS-CoV-2 spike glycoprotein, blocking viral entry into host cells. We aimed to evaluate the efficacy and safety of casirivimab and imdevimab administered in combination in patients admitted to hospital with COVID-19. Methods: RECOVERY is a randomised, controlled, open-label platform trial comparing several possible treatments with usual care in patients admitted to hospital with COVID-19. 127 UK hospitals took part in the evaluation of casirivimab and imdevimab. Eligible participants were any patients aged at least 12 years admitted to hospital with clinically suspected or laboratory-confirmed SARS-CoV-2 infection. Participants were randomly assigned (1:1) to either usual standard of care alone or usual care plus casirivimab 4 g and imdevimab 4 g administered together in a single intravenous infusion. Investigators and data assessors were masked to analyses of the outcome data during the trial. The primary outcome was 28-day all-cause mortality assessed by intention to treat, first only in patients without detectable antibodies to SARS-CoV-2 infection at randomisation (ie, those who were seronegative) and then in the overall population. Safety was assessed in all participants who received casirivimab and imdevimab. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). Findings: Between Sept 18, 2020, and May 22, 2021, 9785 patients enrolled in RECOVERY were eligible for casirivimab and imdevimab, of which 4839 were randomly assigned to casirivimab and imdevimab plus usual care and 4946 to usual care alone. 3153 (32%) of 9785 patients were seronegative, 5272 (54%) were seropositive, and 1360 (14%) had unknown baseline antibody status. 812 (8%) patients were known to have received at least one dose of a SARS-CoV-2 vaccine. In the primary efficacy population of seronegative patients, 396 (24%) of 1633 patients allocated to casirivimab and imdevimab versus 452 (30%) of 1520 patients allocated to usual care died within 28 days (rate ratio [RR] 0·79, 95% CI 0·69–0·91; p=0·0009). In an analysis of all randomly assigned patients (regardless of baseline antibody status), 943 (19%) of 4839 patients allocated to casirivimab and imdevimab versus 1029 (21%) of 4946 patients allocated to usual care died within 28 days (RR 0·94, 95% CI 0·86–1·02; p=0·14). The proportional effect of casirivimab and imdevimab on mortality differed significantly between seropositive and seronegative patients (p value for heterogeneity=0·002). There were no deaths attributed to the treatment, or meaningful between-group differences in the pre-specified safety outcomes of cause-specific mortality, cardiac arrhythmia, thrombosis, or major bleeding events. Serious adverse reactions reported in seven (<1%) participants were believed by the local investigator to be related to treatment with casirivimab and imdevimab. Interpretation: In patients admitted to hospital with COVID-19, the monoclonal antibody combination of casirivimab and imdevimab reduced 28-day mortality in patients who were seronegative (and therefore had not mounted their own humoral immune response) at baseline but not in those who were seropositive at baseline. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

BACKGROUND: In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. METHODS: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. Those trial participants with hypoxia (oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein ≥75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 mg–800 mg (depending on weight) given intravenously. A second dose could be given 12–24 h later if the patient's condition had not improved. The primary outcome was 28-day mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). FINDINGS: Between April 23, 2020, and Jan 24, 2021, 4116 adults of 21 550 patients enrolled into the RECOVERY trial were included in the assessment of tocilizumab, including 3385 (82%) patients receiving systemic corticosteroids. Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0·85; 95% CI 0·76–0·94; p=0·0028). Consistent results were seen in all prespecified subgroups of patients, including those receiving systemic corticosteroids. Patients allocated to tocilizumab were more likely to be discharged from hospital within 28 days (57% vs 50%; rate ratio 1·22; 1·12–1·33; p<0·0001). Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (35% vs 42%; risk ratio 0·84; 95% CI 0·77–0·92; p<0·0001). INTERPRETATION: In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes. These benefits were seen regardless of the amount of respiratory support and were additional to the benefits of systemic corticosteroids

Observations of trace gases and aerosols over the Indian Ocean during the monsoon transition period

Characteristics of trace gases (O3, CO, CO2, CH4 and N2O) and aerosols (particle size of 2.5 micron) were studied over the Arabian Sea, equatorial Indian Ocean and southwest part of the Bay of Bengal during the monsoon transition period (October-November, 2004). Flow of pollutants is expected from south and southeast Asia during the monsoonal transition period due to the patterns of wind flow which are different from the monsoon period. This is the first detailed report on aerosols and trace gases during the sampled period as the earlier Bay of Bengal Experiment (BOBMEX), Arabian Sea Monsoon Experiment (ARMEX) and Indian Ocean Experiments (INDOEX) were during monsoon seasons. The significant observations during the transition period include: (i) low ozone concentration of the order of 5 ppbv around the equator, (ii) high concentrations of CO2, CH4 and N2O and (iii) variations in PM2.5 of 5-20&#956;g/m3